Ask AI
Improving Symptoms of Cachexia

CE / CME

Improving Appetite, Lean Body Mass, or Physical Function in Patients With Cancer Cachexia

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

European Learners: 0.25 EBAC® CE Credit

Released: March 20, 2026

Expiration: September 19, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Josep M. Argilés, PhD, reviews optimal ways to improve appetite, lean body mass, and physical function to optimize treatment outcomes and quality of life for patients with advanced cancer and cachexia. This topic was presented by Professor Argilés during a previously held virtual-live webinar titled, “Global Expert Think Tank: Hope on the Horizon? Key Evidence and Real-world Insights to Optimize the Diagnosis and Treatment of Cancer Cachexia.”

Please note that the key points discussed in this module are illustrated with thumbnails from an accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

For a patient with advanced cancer and cancer-related cachexia who has lost ≥5% weight and is experiencing significant fatigue with progressive loss of muscle mass within 6 months of receiving anticancer chemotherapy, each of the following treatment recommendations should be considered EXCEPT: